Today on Living on the Spectrum, we cover new research into drug repurposing for autism-linked genetic variants, the definitive dismissal of the epidural-autism myth, and the complex relationship between ADHD symptoms and hormonal changes across the lifespan.
Drug Screening in Zebrafish Targets Autism-Linked Gene Behaviors
Research Findings
Researchers identified 376 compounds that alter behavioral patterns associated with autism-linked gene variants. Using an automated platform, the study tested 520 FDA-approved drugs on zebrafish with mutations in nine specific genes. Variants in SCN2A and DYRK1A produced the most distinct behaviors, including nighttime hyperactivity and hypersensitivity to light. Compounds such as estropipate, paclitaxel, and the mitochondrial modulator levocarnitine showed potential in counteracting these effects.
Significance for Precision Medicine
The study highlights the necessity of tailored treatments, as certain medications that helped one genetic profile worsened behaviors in another. While the compounds did not fully reverse the behavioral effects, the findings suggest that repurposing existing drugs could streamline the path to clinical use. Testing levocarnitine on human nerve cells with similar genetic variants further supported its potential role in managing specific neurodevelopmental pathways.
Large-Scale Studies Dismiss Association Between Epidurals and Autism
Background of the Controversy
A 2020 study in JAMA Pediatrics claimed that epidural analgesia during labor increased the likelihood of an autism diagnosis by 37 percent. This claim faced immediate criticism for failing to account for maternal psychiatric history and other confounding factors. The scientific community raised concerns that the data could lead to a misinformation crisis similar to previous debunked claims regarding vaccines.
Evidence from Sibling Analysis
Subsequent studies involving millions of births in Canada and Scandinavia found no meaningful link between epidurals and autism. Researchers used sibling analyses to control for shared genetics and environmental factors, demonstrating that the perceived association disappeared when familial context was included. Professional medical societies now advise parents that the original findings resulted from residual confounding rather than a causal relationship.
How Hormonal Shifts and Gender Bias Impact ADHD Management
Diagnostic Disparities for Females
Clinical tools often overlook ADHD in girls and women because they focus on externalized hyperactivity common in males rather than inattention and executive dysfunction. Many females mask their symptoms to meet social expectations, leading to delayed diagnosis or misdiagnosis as anxiety or depression. Research indicates that females with ADHD face higher risks of suicide attempts, self-injury, and unplanned pregnancy compared to neurotypical peers, yet the male-to-female diagnosis ratio only begins to equalize in adulthood.
Hormonal Influence on Symptoms
Fluctuating estrogen and testosterone levels significantly alter ADHD symptoms and medication efficacy. During puberty, hormonal shifts can heighten impulsivity while the prefrontal cortex is still maturing. In women, low estrogen levels during the menstrual cycle often lead to worsened symptoms and reduced effectiveness of stimulant medications. These biological changes also occur during pregnancy, postpartum, and menopause, where ADHD symptoms frequently peak and may be misattributed to aging or mood disorders.
Strategies for Emotional Resilience
Managing ADHD requires addressing emotional dysregulation and Rejection Sensitive Dysphoria (RSD). Families can support adolescents by setting clear boundaries while practicing non-judgmental listening to foster confidence. Experts suggest that individuals track their menstrual cycles alongside sleep and lifestyle factors to identify patterns in symptom severity. This data allows for more informed adjustments to medication, such as switching to non-stimulants or adjusting dosages during specific hormonal phases to maintain stability.
Podcast Transcript
Aaron: Hello everyone, and welcome to the podcast. I am Aaron.
Jamie: And I am Jamie.
Aaron: We have quite a lot to go through today. Lately, my feed has been filled with headlines about new research into Autism and ADHD, ranging from drug trials to some pretty heavy discussions about how we diagnose girls and women. It can feel a bit overwhelming to keep up.
Jamie: It really can. And what is interesting is that some of these stories are about moving forward with new discoveries, while others are about correcting things we thought we knew in the past. It is a lot to process for any family trying to navigate these paths.
Aaron: Actually, that is a great place to start—correcting the past. Jamie, I remember a few years ago there was this massive wave of anxiety around the idea that getting an epidural during labor might be linked to autism. I still hear parents bring it up in a sort of hushed, worried way. Did we get any more clarity on that?
Jamie: We did, and it is actually one of those rare moments in science where we can say the matter is largely considered closed. Back in 2020, there was a study that suggested a 37 percent increase in autism risk for children whose mothers had epidurals. It caused a lot of alarm, but the scientific community responded very quickly with much larger studies.
Aaron: Right, because once that kind of fear is out there, it is hard to reel back in. What did the follow-up research find?
Jamie: They looked at millions of births—literally millions, across Canada and Scandinavia. One of the most important things they did was "sibling analysis." They compared siblings where one was born with an epidural and the other wasn't. When they accounted for shared genetics and the home environment, that 37 percent increase basically vanished. The original study likely missed what we call "confounders," like maternal health history.
Aaron: That is such a huge relief to hear. It feels like one less thing for parents to carry guilt over. It really highlights how a single headline can create a "misinformation crisis" even if the original researchers had good intentions.
Jamie: Exactly. It shows why we need these massive, multi-country studies to really confirm what we are seeing. It moves us away from fear and back toward looking at what is actually happening in the brain and the genes.
Aaron: Speaking of looking at genes, I saw something recently about zebrafish? It sounds a bit sci-fi, but apparently they are being used to test drugs for autism-related genes. What is the connection there?
Jamie: It sounds unusual, but zebrafish are actually great for this because we can observe their behavior and genetics at a large scale. Researchers looked at about 500 existing FDA-approved drugs to see if they could counteract behaviors linked to certain autism-associated genes, specifically SCN2A and DYRK1A.
Aaron: Wait, so they are looking at drugs that already exist for other things? Like "repurposing" them?
Jamie: Precisely. The idea is that if a drug is already approved for something else, the path to using it for neurodevelopmental support is much shorter. They found nearly 400 compounds that had some effect. One example was levocarnitine, which is typically used for metabolism. It showed promise in helping with certain behavioral traits like nighttime hyperactivity in these models.
Aaron: That sounds like a potential game-changer, but I imagine it’s not as simple as "take this pill and the symptoms go away."
Jamie: No, not at all. And the researchers were very careful to say that. These drugs didn't "reverse" everything, and more importantly, they found that a drug that helped one genetic profile might actually make things worse for another. This is why "precision medicine" is the phrase everyone is using now. It’s about tailoring the approach to the specific person’s biology, rather than a one-size-fits-all diagnosis.
Aaron: That makes so much sense. It’s like we are finally moving away from just labeling the behavior and starting to look at the "why" underneath. This actually reminds me of the conversations happening around ADHD right now, especially how it presents so differently in different people.
Jamie: It really does. Particularly when you look at the gap between how we identify ADHD in boys versus girls. For a long time, the "standard" for ADHD was based on hyperactive young boys. But for many girls, it looks like inattention, internal restlessness, or even "hyper-verbality."
Aaron: And they often get very good at "masking" it, don't they? Just trying to blend in and meet social expectations until they just… can't anymore.
Jamie: Yes, masking is a huge part of the female experience with ADHD. Because they aren't necessarily jumping off desks, they get missed. Their struggles might be misattributed to anxiety or depression. But the reality is that the internal toll is very high. Some longitudinal research shows that females with undiagnosed or unsupported ADHD face much higher risks of self-harm, eating disorders, and even difficulties in relationships compared to their neurotypical peers.
Aaron: It feels like there is this "invisible wall" they hit. I’ve heard people talk about how everything seems fine until puberty hits, and then suddenly, things just fall apart.
Jamie: That "perfect storm" of puberty is a very real biological phenomenon. It’s where hormones meet brain development. We know that estrogen plays a significant role in how dopamine—the chemical linked to focus and reward—works in the brain. When estrogen levels fluctuate, like during a menstrual cycle or the massive shifts in puberty, ADHD symptoms can skyrocket.
Aaron: I didn't realize there was such a direct link between hormones and how well ADHD medication works.
Jamie: Many people don't. During the luteal phase of the cycle, when estrogen drops, many women and teens find their ADHD symptoms become much harder to manage, and their usual medication might feel less effective. For a teenager whose prefrontal cortex—the part of the brain that handles impulse control—is still under construction, this hormonal surge can be incredibly overwhelming.
Aaron: It sounds like we need to be much more proactive about this. If a parent sees their daughter struggling more at certain times of the month, or suddenly finding life unmanageable at age 12, it’s not just "teenage moodiness."
Jamie: Right. It’s a biological shift. One of the best things families can do is actually quite simple in theory but powerful in practice: tracking. By tracking symptoms alongside the menstrual cycle for a few months, you start to see patterns. You can say, "Oh, I’m not failing; my brain is just handling a hormonal dip right now."
Aaron: That seems like it would take so much of the shame out of it. Instead of "What is wrong with me?" it becomes "This is how my body works."
Jamie: Exactly. It builds what we call "emotional self-efficacy." It gives the person a sense of agency. And for clinicians, that data is gold. It helps them decide if a medication needs to be adjusted or if different support is needed during certain weeks of the month.
Aaron: It’s interesting how our conversation today has gone from huge population studies about epidurals to the very specific, day-to-day tracking of a single person’s cycle. It really shows that understanding neurodiversity is a mix of big science and very personal awareness.
Jamie: It really is. Whether it is debunking old fears, looking at zebrafish for future treatments, or just helping a teenage girl understand her own brain, it’s all about moving toward a more nuanced, respectful way of supporting people.
Aaron: I think that is a perfect place to wrap up for today. This is a lot to digest, but it feels like the direction we are moving in is one of more clarity and less blame.
Jamie: I agree. It’s about looking at the facts and the individual, rather than the labels.
Aaron: Thank you for joining us today. If you want to dive deeper into any of the research or topics we discussed, you can find the summaries and original links on our episode page or our website. We will see you next time.
Jamie: Goodbye, everyone.
References
- Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
- A questionable study linked epidurals to autism. Then what?
- ADHD and the Turbulence of Puberty
- Protecting the Emotional Health of Girls with ADHD
- Why Female Symptoms Slip Through Diagnostic Cracks
- Hormones and ADHD
- Menstrual Cycle Workbook for Women with ADHD